New developments in the pathogenesis of preeclampsia.
Preeclampsia affects 3% to 5% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality worldwide. This disorder is characterized by a constellation of signs and symptoms, most notably new-onset hypertension and proteinuria during the last trimester of pregnancy. In this review, the molecular mechanisms of preeclampsia with an emphasis on the role of circulating antiangiogenic proteins in the pathogenesis of preeclampsia and its complications will be discussed.
Renal, Molecular, and Vascular Medicine Divisions, Department of Medicine, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Mihran V
MV
Naljayan
S Ananth
SA
Karumanchi
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000378:metabolism*; D015703:Antigens, CD / Q000378:metabolism* / Q000502:physiology; D000071063:Endoglin; D005260:Female; D006801:Humans; D010920:Placenta / Q000098:blood supply / Q000378:metabolism*; D011225:Pre-Eclampsia / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D011247:Pregnancy; D011956:Receptors, Cell Surface / Q000378:metabolism* / Q000502:physiology; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000378:metabolism* / Q000502:physiology
D020533:Angiogenesis Inhibitors; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1